Article 1 to 6 out of 6 concerning Affimed Therapeutics AG
Affimed appoints Chief Business Officer(06/10/2008) Affimed Therapeutics AG announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer.Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for ...
Affimed validates antibody target for cancer metastasis(05/14/2008) Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of ...
XOMA and Affimed Sign Antibody Cross-License and Collaboration Agreement(10/05/2006) XOMA Ltd. and Affimed Therapeutics AG have signed a cross-license and collaboration agreement for antibody-related technologies. Financial terms were not disclosed. The agreement provides XOMA with a license under Affimed's antibody library patents ...
Affimed and Dyax Cross-License Antibody Technologies(08/15/2003) Affimed Therapeutics AG and Dyax Corp. announced today that they have entered into a cross-licensing agreement for phage display technologies. Financial terms were not disclosed.The Affimed licensed patents consist of two issued U.S. patents with ...
Top
